Reliable monitoring of minimal residual disease in multiple myeloma:: how specific is flow cytometry?

被引：0
|
作者：
Lioznov, MV [1 ]
Cortes-Dericks, L [1 ]
Fehse, B [1 ]
Zander, AR [1 ]
Kröger, N [1 ]
机构：
[1] Univ Hamburg, Hosp Eppendorf, D-20246 Hamburg, Germany
来源：
BONE MARROW TRANSPLANTATION | 2006年 / 37卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S146 / S147
页数：2
相关论文
共 50 条
  • [1] Minimal residual disease monitoring in multiple myeloma:: How specific is the flow cytometric analysis?
    Lioznov, M.
    Fehse, B.
    Zander, A.
    Kroeger, N.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 203 - 203
  • [2] Minimal residual disease monitoring in multiple myeloma: flow cytometry is the method of choice
    Owen, RG
    Rawstron, AC
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 128 (05) : 732 - 733
  • [3] MINIMAL RESIDUAL DISEASE MONITORING IN MULTIPLE MYELOMA USING POLYCHROMATIC FLOW CYTOMETRY
    Rihova, Lucie
    Varmuzova, Tamara
    Zarbochova, Pavla
    Suska, Renata
    Penka, Miroslav
    Hajek, Roman
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2012, 82B (06) : 404 - 405
  • [4] Minimal Residual Disease Detection by Flow Cytometry in Multiple Myeloma: Why and How?
    Roshal, Mikhail
    SEMINARS IN HEMATOLOGY, 2018, 55 (01) : 4 - 12
  • [5] Minimal residual disease in multiple myeloma: Benefits of flow cytometry
    Galtseva, I. V.
    Davydova, Y. O.
    Kapranov, N. M.
    Julhakyan, H. L.
    Mendeleeva, L. P.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2018, 40 (01) : 12 - 20
  • [6] MINIMAL RESIDUAL DISEASE MONITORING IN MULTIPLE MYELOMA PATIENTS BY FLOW CYTOMETRY: A SINGLE CENTER EXPERIENCE
    Sizikova, S.
    Pronkina, N.
    Batorov, E.
    Ushakova, G.
    Sergeevicheva, V.
    Gilevich, A.
    Kruchkova, I.
    HAEMATOLOGICA, 2017, 102 : 789 - 789
  • [7] Clinical implication of minimal residual disease monitoring by 10-color flow cytometry in multiple myeloma
    姚卫芹
    ChinaMedicalAbstracts(InternalMedicine), 2019, 36 (04) : 231 - 232
  • [8] Flow cytometry immunophenotype is a powerful approach in monitoring minimal residual disease and treatment efficacy in multiple myeloma
    Cordone, I.
    Masi, S.
    Pasquale, A.
    Pisani, F.
    Olimpieri, O. M.
    Marino, M.
    D'Andrea, M.
    Dessanti, M. L.
    Petti, M. C.
    CYTOMETRY PART A, 2008, 73A (01) : 79 - 79
  • [9] Monitoring of minimal residual disease in multiple myeloma:: Flow cytometry vs PCR-based techniques
    Lioznov, M.
    Badbaran, A.
    Fehse, B.
    Zander, A.
    Kroeger, N.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 203 - 203
  • [10] Regulatory Perspective on Minimal Residual Disease Flow Cytometry Testing in Multiple Myeloma
    Gormley, Nicole J.
    Turley, Danielle M.
    Dickey, Jennifer S.
    Farrell, Ann T.
    Reaman, Gregory H.
    Stafford, Elizabeth
    Carrington, Lea
    Marti, Gerald E.
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2016, 90 (01) : 73 - 80
12345